Sellas Life Sciences Group Inc
(SLS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Operating Expenses | 43,900 | 28,489 | 21,199 | 12,486 | 16,620 |
| Operating Income | -43,900 | -28,489 | -21,199 | -12,486 | -16,620 |
| Interest Expense | 1,110 | 0 | 0 | 0 | 0 |
| Other Income | 16,726 | -41,786 | -13,178 | 9,079 | 4,630 |
| Pre-tax Income | -28,284 | -70,275 | -34,377 | -3,407 | -11,990 |
| Income Tax | N/A | 1,052 | -1,052 | N/A | 0 |
| Net Income Continuous | -28,284 | -71,327 | -33,325 | -3,407 | -11,993 |
| Net Income Discontinuous | -8,322 | -5,351 | -1,644 | -8,078 | 0 |
| Net Income | $-36,606 | $-76,678 | $-34,969 | $-11,485 | $-11,990 |
| EPS Basic Total Ops | -9,204.20 | -25,525.52 | -16,816.82 | -9,609.61 | -20,120.12 |
| EPS Basic Continuous Ops | -7,117.12 | -23,723.72 | -15,915.91 | -2,702.70 | -19,988.33 |
| EPS Basic Discontinuous Ops | -2,087.09 | -1,801.80 | -900.90 | -6,606.61 | N/A |
| EPS Diluted Total Ops | -9,204.20 | -25,525.52 | -16,816.82 | -9,609.61 | -20,120.12 |
| EPS Diluted Continuous Ops | -7,117.12 | -23,723.72 | -15,915.91 | -2,702.70 | -19,988.33 |
| EPS Diluted Discontinuous Ops | -2,087.09 | -1,801.80 | -900.90 | -6,606.61 | N/A |
| EBITDA(a) | $-43,814 | $-28,203 | $-21,150 | $-12,323 | $-16,450 |